In patients with cancer, opportunistic infection is a complication leading to morbidity and mortality, especially at their terminal stages 1, [4] [5] [6] . Their poor responses to vaccination 3 also implicate a deficient adaptive immunity. We investigated whether established tumors dispose patients to infection by producing global T cell immunosuppression. After inoculation of Lewis lung cancer (LLC) cells, we initiated viral infection in tumor-bearing mice using lymphocytic choriomeningitis virus (LCMV) of the Armstrong (LCMVArmstrong; Supplementary Fig. 1a ) or clone 13 (LCMV-Cl 13 ) strain. Although tumor-free mice survived infection, by day 9, 80% of tumor-bearing mice had succumbed to infection. This susceptibility is the product of neither LLC nor LCMV exclusively: 90% of B16F10 melanoma-bearing mice succumbed to LCMV infection (Fig. 1a) , and death was also induced in LLC tumor-or B16F10 tumor-bearing mice after Listeria monocytogenes (Lm) infection ( Supplementary Fig. 1b) .
Impaired immunity in patients with late-stage cancer is not limited to antitumor responses, as demonstrated by poor vaccination protection and high susceptibility to infection
. This has been largely attributed to chemotherapy-induced impairment of innate immunity, such as neutropenia 2 , whereas systemic effects of tumors on hematopoiesis and adoptive immunity remain incompletely understood. Here we observed anemia associated with severe deficiency of CD8 + T cell responses against pathogens in treatment-naive mice bearing large tumors. Specifically, we identify CD45 + EPC transcriptome closely resembles that of MDSCs, and, like MDSCs, reactive oxygen species production is a major mechanism underlying CD45 + EPC-mediated immunosuppression. Similarly, an immunosuppressive CD45 + EPC population was detected in patients with cancer who have anemia. These findings identify a major population of immunosuppressive cells that likely contributes to the impaired T cell responses commonly observed in patients with advanced cancer.
In patients with cancer, opportunistic infection is a complication leading to morbidity and mortality, especially at their terminal stages 1, [4] [5] [6] . Their poor responses to vaccination 3 also implicate a deficient adaptive immunity. We investigated whether established tumors dispose patients to infection by producing global T cell immunosuppression. After inoculation of Lewis lung cancer (LLC) cells, we initiated viral infection in tumor-bearing mice using lymphocytic choriomeningitis virus (LCMV) of the Armstrong (LCMVArmstrong; Supplementary Fig. 1a ) or clone 13 (LCMV-Cl 13 ) strain. Although tumor-free mice survived infection, by day 9, 80% of tumor-bearing mice had succumbed to infection. This susceptibility is the product of neither LLC nor LCMV exclusively: 90% of B16F10 melanoma-bearing mice succumbed to LCMV infection (Fig. 1a) , and death was also induced in LLC tumor-or B16F10 tumor-bearing mice after Listeria monocytogenes (Lm) infection ( Supplementary Fig. 1b) .
To determine the impact of tumor establishment on CD8 + T cells during LCMV infection, we infected mice with LCMV-Cl 13 at different time points following LLC inoculation and performed analyses on day 8 postinfection (Fig. 1b) . LCMV viral loads in multiple tissues were well-controlled at early stages of tumor bearing, whereas they were compromised at later tumor stages (Fig. 1c) . LCMV infection is controlled by both antibody-and T cell-mediated responses. The relative numbers of germinal center B cells and splenic T follicular helper (T FH ) cells were not altered by tumor implantation ( Supplementary Fig. 2a-e) . However, the number of antigen-specific interferon-γ (IFN-γ )-producing CD4 + T cells was substantially decreased ( Supplementary Fig. 2f,g ). With prolonged tumor bearing, both the frequency and absolute number of CD8 + T cells specific for all dominant LCMV class I epitopes and their capacity for IFN-γ production were also significantly reduced (Fig. 1e,f) . Similarly, decreases in ovalbumin (OVA)-specific CD8 + T cell responses were also observed in tumor-bearing mice after infection with OVA-expressing Lm ( Supplementary Fig. 3a-c) .
To directly assess cancer-associated T cell functional impairment in vivo, effector T cells (CD8 + CD44 + PD-1 hi ) were purified from LCMV-infected tumor-free or tumor-bearing mice and cotransferred with peptide-loaded splenocytes. We observed a compromised killing capacity of effector CD8 + T cells from tumor-bearing mice against two dominant LCMV antigens (Fig. 1g ). These results demonstrate that, in tumor-bearing mice, deficient protection against infection is accompanied by impaired CD8 + T cells. To elucidate the mechanisms underlying this impaired T cell response, we analyzed mouse spleens at different durations of tumor T u m o r -f r e e T u m o r -b e a r i n g P = 0.0025 P = 0.0003 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Fig. 1 | increased susceptibility to LCMV-Cl 13 infection and decreased immune responses by CD8
+ T cells in tumor-bearing mice. a, Survival of tumor-bearing mice (inoculated with LLC or B16F10 cells, n = 10), tumor-free mice (n = 10) after LCMV-Cl 13 infection, and uninfected tumor-bearing control mice (Ctrl; n = 10) was monitored. b-e, Mice were infected with LCMV-Cl 13 at different times following LLC inoculation (0, 7, 14, and 21 d) and euthanized on day 8 postinfection (b). Viral load (in plaque-forming units, PFU) in the indicated tissues, including spleen, liver and lung, at 21 d after tumor implantation (Tumor free, n = 7 (spleen), n = 6 (liver and lung); day 7 (D7), n = 7 (spleen), n = 6 (liver), n = 8 (lung); D14, n = 7 (spleen and liver), n = 6 (lung); D21, n = 8 (spleen and lung), n = 7 (liver)) (c). Antigen-specific CD8 + T cells (top) and production of IFN-γ by splenic CD8 + T cells after stimulation with viral antigen (bottom), determined via staining for intracellular IFN-γ -and LCMV-specific tetramers (d); and the frequency and the total number of IFN-γ -producing and antigen-specific CD8 + T cells in the spleens of tumor-bearing mice (e; n = 5). f, Mice were infected with LCMV-Cl 13 at day 21 following LLC inoculation and euthanized on day 8 postinfection. Antigen-specific CD8 + CD44 + PD-1 hi cells recognizing each epitope were determined using LCMV-epitope-specific tetramers (n = 5). g, The ability of CD8 + T cells isolated from LCMV-Cl 13 -infected tumor-bearing or control mice to kill viral-peptide-pulsed splenocytes in vivo was analyzed (n = 5). Each point in c and e represents data from an individual mouse, and the data are representative of three independent experiments. n values are the number of mice used to obtain the data. Two-tailed Student's t-tests were used for all comparisons, with the exception of survival curves, for which Gehan-Breslow-Wilcoxon tests were used. Two-tailed P values are reported. Bar graphs denote mean values with s.e.m.
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bearing. Although we observed splenomegaly at the later stages, this increase in spleen size was not associated with increases in lymphocyte populations: instead, B cell, CD4
+ and CD8 + T cell frequencies were reduced (Fig. 2a) . In accordance with previous reports 7, 8 , MDSCs and tumor-associated macrophages increased with tumor progression (Fig. 2a and Supplementary Fig. 4) . Surprisingly, spleen size increase was mainly attributed to CD71 + TER119 + EPCs: CD71 +
TER119
+ cells comprised 5-10% of splenocytes in tumorfree mice, whereas they accounted for 40-60% of total splenocytes in mice with advanced tumors (Fig. 2a) . During tumorigenesis, EPCs also steadily accumulated in bone marrow, liver, and blood, but not in lymph nodes or tumor tissues ( Supplementary Fig. 5a,b) . Notably, in spleens, the quantity of EPCs was higher than MDSCs and T reg s, two established immunosuppressive populations, by ~ 3-and 30-fold, respectively (Fig. 2b) .
In neonatal mice, EPCs compromise innate immune function, resulting in susceptibility to infection 9 . To test whether EPCs are responsible for impaired CD8
+ T cell responses, we performed an in vitro suppression assay against CD8 + T cells from tumor-free mice. Splenic CD71 + TER119 + EPCs from mice bearing day 21 tumors are robustly immunosuppressive: T cell proliferation was suppressed by ~ 50% at a suppressor:effector ratio of 1:1, and a 2:1 ratio reliably ablated CD8 + T cell proliferation (Fig. 2c) . EPCs also inhibited CD4 + T cell proliferation and T H 1 differentiation ( Supplementary Fig. 6 ).
Erythrocytes are normally generated in bone marrow, but stresses such as anemia 10 , pregnancy 11 , and infection 12 require a rapid increase of these cells. Through a process called 'extramedullary erythropoiesis' , erythroid differentiation can be initiated in the liver and spleen [13] [14] [15] . We collected blood following tumor cell inoculation and found that hematocrit and hemoglobin (HGB) levels and mature RBC counts decreased with prolonged tumor bearing ( Fig. 2d and Supplementary Fig. 7 ). Moreover, blood HGB level inversely correlated with splenic EPCs (Fig. 2e) . Thus, splenic EPC enrichment may result from tumor-initiated anemia and compensatory extramedullary erythropoiesis.
Extramedullary erythropoiesis is also induced during early embryonic development or by acute anemia 10, 16 ( Supplementary  Fig. 5a ). Although phenyl hydrazine induced acute anemia within 3 d and caused CD71 + TER119 + cell accumulation in multiple organs, including spleen, antigen-specific CD8 + T cell responses against infection remained unimpaired ( Supplementary Fig. 8 ). 
+ group n = 5), and data were analyzed by two-tailed unpaired t-test. Tumor-infiltrating leukocytes were enriched and loaded with the OVA 257-264 (SIINFEKL) peptide in vitro for 24-h restimulation, and frequencies of IFN-γ -and tumor necrosis factor-α (TNF-α )-producing T cells were analyzed by intracellular cytokine staining (k); each point represents data from an individual mouse (n = 3), and data were analyzed by two-tailed unpaired t-test. l-n, A total of 1 × 10 6 LLC cells were subcutaneously injected into C57BL/6 mice (PBS was used as control). Anti-CD71 antibody (1 mg/mouse) was i.v. injected at day 21 after tumor cell inoculation (IgG was used as control, 1 mg/mouse). To attenuate the anti-CD71 antibody, anti-IgG2a antibody (3 mg/ mouse) was i.v. injected 24 h later. Finally, we adoptively transferred P14 CD8 + T cells (CD90.1, 2 × 10 6 cells/mouse) into mice and simultaneously infected them with LCMV-Cl 13 36 h after administration of anti-CD71 antibody (α CD71). All mice were euthanized at day 2 after LCMV infection (l). 
+ cells (p) in the peripheral blood of MMTV-PyMT female mice, which developed palpable mammary tumors at 12 weeks old, were determined at different weeks after birth (10, 12, 14, 16, 18, 20) . The proliferative capacity of CFSE-labeled CD8 + T cells in response to anti-CD3 and anti-CD28 was analyzed after coculture with CD45 
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The number of splenic EPCs was smaller in acutely anemic mice than in mice carrying established tumors ( Supplementary Fig. 5a ). The EPCs from those anemic mice were also less suppressive at the per-cell level: more CD71 + TER119 + cells from anemic mice were needed to suppress CD8 + T cell proliferation than CD71 + TER119 + cells from tumor-bearing mice ( Supplementary Fig. 9a ), whereas the suppressive capacity of EPCs in neonatal spleen was lower in EPCs from acutely anemic than from tumor-bearing mice ( Supplementary Fig. 9b ,c).
We hypothesized that the varying immunosuppressive capacity of EPCs from these three conditions results from distinct stages of EPC maturity. During erythroid development, CD45 
TER119
+ cells (b) from tumor-bearing (n = 3), anemic (n = 3), and neonatal (n = 3) mice. An expectation maximization algorithm was used to perform clustering under Gaussian mixture models. The contour shows the estimated probability density for each group. Log-likelihood is shown. c, Pathway enrichment analysis was performed using Gene Set Enrichment Analysis (GSEA). Significantly enriched (nominal P < 0.05) items in CD45 + precursors at undifferentiated stages, and its expression is a hallmark of early precursors 17, 18 . Accordingly, within the splenic EPC population, CD45
+ progenitors were more abundant in tumor-bearing and neonatal mice than in mice with acute anemia (Fig. 2f) . In comparison to other immunosuppressive cells in spleen, the ratio of CD45 +
CD71
+ TER119 + cells to CD4 + and CD8 + T cells was comparable to MDSCs and much higher than T reg s (Fig. 2g) ) and performed in vitro cytotoxicity assays with CD45
+ or CD45 -EPCs isolated from tumor-bearing mice. Indeed, cytotoxic T lymphocyte (CTL) suppression resides in the CD45 + EPC population (Fig. 2h) . The superiority of CD45 + EPCs in suppressing CD8
+ T cells was validated using anti-CD3/CD28 antibody-stimulated and cognate antigen-induced in vitro proliferation assays ( Supplementary Fig. 11a,b) . Additionally, after equal numbers of CD45 -or CD45 + EPCs were cotransferred with P14 transgenic CD8 + T cells into recipient mice, LCMV-specific T cell proliferation in vivo was only inhibited by CD45
+ EPCs (Fig. 2i) . Quantitatively, the suppressive capacity of CD45 + EPCs falls between T reg s and MDSCs ( Supplementary Fig. 11c ).
Compared to anemic and neonatal conditions, tumor establishment leads to a much higher accumulation of CD45 + EPCs, which are selectively enriched in the spleen and bone marrow and possess strong suppressive capacity ( Supplementary Fig. 11d-g ). When transferred into recipient mice at an early stage of tumorigenesis, CD45
+ EPCs accelerated B16 melanoma tumorigenesis (Fig. 2j) , which was associated with impaired activation of infiltrating tumorantigen-specific CD8 + T cells (Fig. 2k) . Similarly, using OVA as a surrogate tumor antigen, we observed that both proliferation and cytotoxicity of OT-I T cells were suppressed in the spleen, suggesting that CD45
+ EPCs also suppress tumor antigen-elicited CTL priming ( Supplementary Fig. 12 ). We further validated the relevance of this population in vivo through anti-CD71 antibody-aided EPC depletion. Although CD71 is also expressed in activated CD8 + T cells ( Supplementary Fig. 13a-g ), to preserve CTL activity we blocked the crystallizable fragment (Fc) region of the anti-CD71 antibody (IgG2a) upon EPC depletion ( Supplementary Fig. 13h,i) . Following IgG2a blockade, P14 CD8 + T cells were transferred to recipient mice, which were simultaneously infected with LCMV-Armstrong (Fig. 2l) . Efficient EPC depletion ( Supplementary Fig. 13j ) rescued the proliferation of LCMV-specific CD8 + T cells (Fig. 2m,n) , providing direct evidence that EPCs suppress antiviral CTL responses in tumor-bearing mice. We further monitored the development of CD45 + EPCs in MMTV-PyVT transgenic mice 20 , in which breast tumors developed spontaneously in 12 weeks. At week 20, CD45 + EPCs were significantly enriched in the peripheral blood, liver and spleen of mice, accompanied with anemia (Fig. 2o,p) . These CD45 + EPCs were also robust suppressors of CTL proliferation and killing (Fig. 2q,r) . These findings pinpoint the origin of systemic immunosuppression in tumor-bearing mice as CD45
+ EPCs. Additionally, we observed that established tumors not only induce anemia, but also arrest the development of CD45 + EPCs (Supplementary Fig. 14) . Although CD45 + EPCs from tumor-bearing mice and neonatal mice carry the same surface marker, those from the former were more robust suppressors and were much more powerful than those from acute anemic mice (Fig. 2s) .
To uncover the molecular mechanisms underlying immunosuppression by CD45
+ EPCs, we performed RNA sequencing (RNAseq) using CD45
+ and CD45 -EPCs generated by the spleens of anemia, tumor-bearing and neonatal mice. We included MDSCs, another bone marrow-derived immunosuppressor 21 , from spleens of tumor-bearing mice as a control. Although both populations contained heterogeneous erythroid cells across developmental stages, the global gene expression patterns of CD45 + EPCs differed significantly from their CD45 -counterparts (Fig. 3a) , especially for signature genes defining the erythrocyte lineage and immunosuppression ( Supplementary Fig. 15 ).Within the CD45 + EPC pool, cells from tumor-bearing, neonatal and anemic mice were further separated, whereas CD45 + EPCs and MDSCs from tumor-bearing mice closely resembled one another (Fig. 3b) . Indeed, for the MDSC immunosuppression signature genes, CD45
+ cells isolated from tumor-bearing or neonatal mice were indistinguishable from MDSCs ( Supplementary Fig. 15b ).
Subsequent analysis of these datasets identified enrichment in the reactive oxygen species (ROS) pathway (Fig. 3c,d) . In a comprehensive comparison, the expression of signature genes for ROS production and removal were very similar between CD45 + EPCs and 
CD235a
+ and CD45 -CD71
+
CD235a
+ cells from patients with cancer was analyzed by flow cytometry (left), and the MFI of the fluorescent dye for detecting ROS was quantified (right) (n = 11). DCF, 2′ ,7′ -dichlorofluorescin. m,n, CD8 + T cell proliferation after stimulation with anti-CD3 and anti-CD28 was measured using CFSE-labeled CD8 + T cells cultured alone or cocultured with CD45
+ cells at a 1:1 ratio, with or without the ROS inhibitor apocynin. Representative FACS plots of results are shown (m). The percentage of cells in each generation was calculated, and a two-tailed unpaired t-test of four independent experiments was performed by measuring the distribution of CD8 + T cells in each division (n). Each point in b-d and g-i represents data from an individual patient. n values are the number of patients from whom data was obtained. Data are representative of three independent experiments and were analyzed by a two-tailed unpaired t-test. Two-tailed P values were reported. Error bars denote the s.e.m.
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MDSCs (Fig. 3e) . Excessive ROS production is a well-established mechanism for MDSC-mediated T cell immunosuppression 22, 23 , in which the NOX family of ROS-generating NADPH oxidases, including NOX2, play an essential role 23, 24 . Indeed, compared to their CD45 -counterparts, NOX2 expression is markedly higher in CD45
+ EPCs (Fig. 3f) . Accordingly, ROS levels are significantly elevated in CD45 + EPCs (Fig. 3g) . Although intracellular ROS are necessary for optimal TCR activation 25 , excessive intracellular 26 and environmental 21 ROS are detrimental to effector T cell responses. Consequently, apocynin, a NADPH oxidase inhibitor 25, 27 , released the CD45 + EPC blockade to restore CTL proliferation (Fig. 3h ,i) and killing (Fig. 3j) . These results suggest that, like in MDSCs, ROS Letters NaTuRE MEDICINE represent a major mechanism through which CD45 + EPCs execute immunosuppression.
Next, we investigated the clinical relevance of EPCs. EpsteinBarr virus (EBV) is a common latent virus infecting most human populations, and control of viremia relies on EBV-specific CTLs 28, 29 . We collected peripheral blood from 167 patients with cancer and examined EBV viremia and EBV-specific CTL responses. For this cohort, EBV reactivation was significantly increased in patients with moderate to severe anemia (Fig. 4a) . Moreover, within the subgroup of EBV-reactivated patients, EBV copy number inversely correlated with blood HGB level (Fig. 4b) . Their CD8 + T cell responses against the major antigenic EBV proteins, LMP2 and EBNA1, were significantly suppressed (Fig. 4c,d ). Human EPCs can be identified by CD71 + CD235a + expression 9 . The frequency of EPCs in peripheral blood was increased in patients with cancer who have moderate to severe anemia (Fig. 4e,f) , which is inversely correlated with HGB concentration (Fig. 4g) . In patients with moderate to severe anemia, CD45 + CD71 + CD235a + cells were detected in every individual, with an average frequency of 6% within the EPC pool and 0.4% among all peripheral blood mononuclear cells (PBMCs; Fig. 4h ). These cells were also inversely correlated with the blood HGB level (Fig. 4i) . As in mice, the ROS signature (Fig. 4j) , and specifically NOX2 (Fig. 4k) 
expression, in human CD45
+ EPCs was significantly elevated compared to CD45 -cells. Mechanistically, CD45
+ EPCs are robust ROS producers (Fig. 4l) and suppressors of TCR-stimulated CD8
+ proliferation, and this immunosuppression is ROS-dependent (Fig. 4m,n) . Although we do not have access to spleens from these patients, we reasoned that human CD45
+ EPCs functionally mirror their murine counterparts.
In summary, on the basis of clinical observations, we recapitulated the systemic suppression of CD8 + T cell activation and enhanced susceptibility to infection in animals bearing established tumors. During mouse tumor progression, as recently reported 30 , an unusual cell type, the CD71 + TER119 + EPC, becomes dominant in the spleen; in patients with cancer who are anemic, CD71 + CD235a + less-differentiated progenitor within the EPC population behaves as a potent MDSC-like immunosuppressor by impairing both CD8 + T cell priming in the spleen and effector function in peripheral tissues, eventually causing the systemic impairment of CD8 + T cell function. Because this population vastly outnumbers T reg and is at least equal to MDSCs in size and immunosuppressive activity, we believe that EPCs should not be ignored in therapeutic strategies aimed at enhancing adaptive immunity of patients with cancer.
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Methods
Cell lines and cell culture. LLC cells and B16F10 melanoma cells were obtained from the American Type Culture Collection (ATCC), and their identity was verified before experiments were conducted. Cells were cultured in DMEM/H (HyClone) containing 10% FBS (Gibco) and 1% penicillin/streptomycin (Beyotime Biotechnology) and incubated at 37 °C in a humidified atmosphere with 5% CO 2 . Cell lines were routinely validated and were free of mycoplasma contamination.
Human sample collection and processing. Peripheral blood was collected from healthy adult volunteers and patients with cancer under Xinqiao Hospital Medical Center Institutional review board (IRB)-approved protocols (no. 2013047). Written informed consent was provided from all study participants before sample collection. All peripheral blood collections were performed before any transfusion, even for anemic patients. Mononuclear cells were freshly isolated over lymphocyte separation medium. CD8
+ T cells and CD45 + CD71 + CD235a + cells were sorted as described below. No statistical method was used to predetermine sample size.
Tumor and anemia animal models. OT-1 transgenic C57BL/6J mice were obtained from Jackson Laboratories. P14 (CD90.1) TCR transgenic mice were obtained from R. Ahmed at Emory University. Both male and female mice, aged 6-8 weeks, were included in each experiment. To determine the size of animal groups, pilot experiments were performed without statistical estimation. For repeat experiments, we used the JMP statistical package to perform power analysis to determine the group size. Based on results from pilot studies, we used parameters of alpha = 0.05; power = 80%; effect size = 50%; and s.d. = 30% of the mean.
To establish an in vivo tumor model, 1 × 10 6 LLCs or 5 × 10 5 B16F10 cells were resuspended in 150 µ L PBS and subcutaneously injected into the right flank of C57BL/6 mice. Tumor-bearing mice were infected with or without pathogens at different time points postinoculation. For LLC tumors, the average tumor volumes were 67.14 ± 20.10 mm 3 at day 7, 195.01 ± 55.39 mm 3 at day 14, 621.53 ± 155.14 mm 3 at day 21, and 1,888.85 ± 402.95 mm 3 at day 28. For B16F10 tumors, average tumor volumes were 110.11 ± 24.16 mm 3 at day 7, 610.60 ± 141.44 mm 3 at day 14, and 2,411.24 ± 346.66 mm 3 at day 21. To induce anemia, C57BL/6 mice were injected intraperitoneally (i.p.) on day 0 with 50 mg phenylhydrazine hydrochloride solution in 200 µ L PBS per kg body weight. Blood (10 µ L) was obtained from the tail vein on day 3 for hematocrit, hemoglobin, and red blood cell count measurements. Mice were infected with LCMV or Lm. All mice were used in accordance with the institutional biosafety regulations and guidelines of the Institutional Animal Care and Use Committees of the Third Military Medical University.
Animal infection models. The LCMV-Armstrong and LCMV-Cl 13 strains were gifts from R. Ahmed at Emory University. Recombinant Lm expressing OVA (rLmOVA) and actA-deficient rLmOVA (Δ actArLmOVA) were kindly provided by J. Harty (University of Iowa, Iowa City, IA).
Mice were infected i.v. with LCMV-Armstrong (2 × 10 5 PFU) or i.p. with LCMV-Cl 13 (2 × 10 6 PFU) at different time points (days 0, 7, 14, 21) after LLC cell inoculation. All mice were euthanized on day 8 after LCMV infection. To assess susceptibility to Lm infection in tumor-bearing mice, mice were intravenously inoculated with a sublethal dose of 4 × 10 6 CFU Δ actArLmOVA per mouse at different time points (days 0, 7, 14, 21) after LLC cell inoculation. All mice were euthanized on day 7 after Δ actArLmOVA infection. To assess immune responses to Lm infection in anemic mice, mice were intravenously injected with a dose of 4 × 10 6 CFU Δ actArLmOVA per mouse at different time points. All mice were euthanized on day 7 after Δ actArLmOVA infection. For both LCMV and Lm infection, tumor-bearing mice were allocated into different groups based on computer-generated randomization.
Virus titration. The viral loads of LCMV-Armstrong were titrated by plaque assay as previously described 28 . For quantification of LCMV-Cl 13 loads, the weight of harvested tissues from infected mice was measured. After homogenization, total RNA was then extracted from the tissue homogenate using TIANAMP Virus RNA Kit (TIANGEN, China) and was subjected to reverse transcription using the RevertAid Minus First Strand cDNA Synthesis Kit (Thermo, USA) following the manufacturer's instructions, and LCMV-specific glycoprotein primer (GP-R: 5′ -GCAACTGCTGTGTTCCCGAAAC-3′ ) was used for cDNA synthesis. RT-qPCR with LCMV glycoprotein-specific primer pairs (GP-R, 5′ -GCAACTGCTGTGTTCCCGAAAC-3′ , and GP-F 5′ -CATTCACCTGGACTTTGTCAGACTC-3′ ) was then used to evaluated viral loads in tissue samples. The Cq (quantification cycle of qPCR) values from RNA samples of tenfold serially diluted LCMV-Armstrong that had been previously titrated by plaque assay 28 was used to generate a standard curve. The PFU of LCMV-Cl 13 in tissues was calculated according to the formula: log 10 (PFU) = slope × Cq + y intercept; PFU / g tissue weight = PFU calculated from above formula / tissue weight. Cq is the cycle at which the fluorescence of the sample is first above baseline fluorescence.
Survival analysis. 14 d after LLC cell inoculation or 10 d after B16F10 melanoma cell inoculation, mice were injected i.v. with 2 × 10 5 CFU rLmOVA in 300 mL saline or i.p. with LCMV-Cl 13 (2 × 10 6 PFU).Uninfected tumor-bearing mice and infected C57BL/6 mice without tumor cells were used as controls. All mice were monitored twice daily.
Adoptive transfer. CD8 + OT-1 cells were enriched (> 90%) from splenocytes by immunodepletion of CD8 -cells using a CD8a + T Cell Isolation Kit II (Miltenyi Biotec) according to the manufacturer's instructions. Groups of congenic recipient mice were injected i.v. with equivalent numbers of their respective CD8
+ OT-1 cell subpopulations.
Flow cytometry. Antibody staining was performed in PBS containing 2% BSA or FBS (wt/vol). For analysis of cytokine production, splenocytes were first stimulated with GP33 peptide (amino acid sequence: KAVYNFATC; 0.2 μ g/mL) in the presence of brefeldin A for 5 h at 37 °C. Following surface staining, intracellular cytokine staining was performed with a Cytofix/Cytoperm Fixation/ Permeabilization kit (554714, BD Biosciences) according to the manufacturer's instructions. To detect degranulation, splenocytes were stimulated for 5 h with the indicated peptide (0.2 μ g/mL), in the presence of brefeldin A and anti-CD107a/b antibodies (1D4B, BD Biosciences). Major histocompatibility complex (MHC) class I peptide tetramers consisting of H-2D b complexed with LCMV GP33-41 were obtained from R. Ahmed (Emory University). Samples were collected using a FACSCanto system (BD Bioscience) and analyzed with FlowJo software (TreeStar).
Antibodies. Fluorophore-or biotin-conjugated antibodies specific for mouse cell-surface antigens and cytokines were as follows: anti-B220 (RA3-6B2, BioLegend), anti-CD4 (GK1.5, BioLegend), anti-CD8a (53-6.7, BioLegend), anti-CD11b (M1/70, BioLegend), anti-Gr1 (RB6-8C5, BioLegend), anti-CD25 (3C7, BioLegend), anti-FOXP3 (MF14, eBioscience), anti-TER119 (TER-119, BioLegend), anti-CD71 (R17 217.1.3, BioXCell for depletion; C2F2, BD biosciences for FACS analysis), anti-CD45 (I3/2.3, BioLegend), anti-CD90.1 (16-10A1, BioLegend), anti-GZMB (GL1, BioLegend), anti-IFN-γ (XMG1.2, BioLegend). anti-CXCR5 (L138D7, BioLegend), anti-mouse/human CD44 (IM7, BioLegend), anti-human/mouse BCL-6 (7D1, BioLegend), anti-T-bet (4B10, BioLegend), antimouse Ki67 (16A8, BioLegend), and anti-mouse TNF-α (MP6-XT22, BD). For human studies, the following fluorophore-or biotin-conjugated antibodies specific for cell surface markers or cytokines were used: anti-CD3 (UCHT, BioLegend), anti-CD8 (PRA-T8, BioLegend), anti-CD45 (2D1, BioLegend), anti-CD71 (CY1G4, BioLegend), and anti-CD235a (HI264, BioLegend). ROS production was measured by labeling with 2′ ,7′ -dichlorofluorescin diacetate using the ROS detection kit (S0033, Beyotime).
Cell sorting and in vivo killing assay. Cell sorting was performed on a FACSAriaII sorter (BD Biosciences). The purity of all populations was > 95%. In vivo killing assays were performed as previously described 29 . Unless otherwise specified, the effector:target (E:T) ratio was set as 4:1 and determined by normalizing all populations to the number of DbGP33 tetramer-positive CD8 + T cells.
Ex vivo killing assay. Ex vivo killing assays were performed as previously described 29 . Peptide-pulsed target cells were mixed with sorted CD8 + T cells at a 4:1 (E:T) ratio, which was determined by normalizing all populations to the number of DbGP33 tetramer-positive CD8 + T cells.
T cell proliferation and coculture. A 96-well plate was coated with a monoclonal antibody to CD3. The antibody was allowed to bind, and then the plate was washed. T cell proliferation was analyzed by labeling with CFSE at a final concentration of 5 µ M (Molecular Probes, Invitrogen), according to the manufacturer's instructions. Briefly, cells were resuspended in warm PBS containing 5 µ M CFSE and incubated at 37 °C for 10 min. Subsequently, cells were washed twice and resuspended in RPMI 1640 containing 10% FBS. CFSE-labeled human PBMCs were added to the wells along with test compound and anti-CD28 antibody to provide costimulation. For coculture analysis, different types of sorted cells were added at different ratios. In some coculture experiments, CD45 + EPCs were treated for 30 min before and during coculture with 300 mM apocynin (49-hydroxy-39-methoxyacetophenone) to inhibit NADPH oxidase. For all experiments, cells were analyzed by flow cytometry after 72 h in culture. For in vivo proliferation assays, P14 (CD45.1
+ T cells were labeled with 2 μ M CFSE according to the manufacturer's instructions (Invitrogen), and 2 × 10 5 P14 cells were mixed with 2 × 10 6 sorted CD45
cells. These mixed cell populations were then adoptively transferred into naive B6 mice immediately, which were subsequently infected with LCMV-Armstrong. Mice were euthanized on day 3 postinfection, and their cell populations were analyzed using flow cytometry.
Real-time quantitative PCR. RNA was extracted using the RNeasy Mini kit (Qiagen), and 1 µ g total RNA was used for first-strand cDNA synthesis. RT-qPCR was performed using a LightCycler instrument (Roche Diagnostics). Primers used for RT-qPCR analysis are listed in Supplementary Table 4 . The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
No specific software was used for data collection.
Data analysis
Flow cytometry results were analyzed by FlowJo_V10(TreeStar). Graphs were prepared and analysized using Graphpad Prism(version 6.0).RT-PCR was analyzed using a LightCycler (Roche Diagnostics). Prepared libraries of RNA-seq were sequenced on an Illumina HiSeq 2000 sequencer and calculated and normalized in FPKM, and used for Gene Set Enrichment Analysis (GSEA, Broad Institute). For Bioinformatic analysis, raw sequence reads were first aligned to the mouse UniGene transcriptome with bowtie (v1.0.0) to estimate the insert fragment size and the standard deviations needed by TopHat2 to align the reads to the genome. Then, TopHat2 was used to align the reads to the reference mouse genome (GRCm38) with the aligning parameter-bowtie1 and Ensembl annotated transcripts (version 77) as a guide reference. Uniquely mapped reads were used to quantify gene expression, and differential gene expression evaluation was analyzed by Cuffdiff(a subpackage of Cufflinks(v2.1.1)) with Ensembl annotated genes (version 77). The abundance of transcripts (including mRNAs, pseudogenes, non-coding RNAs and other predicted RNAs) was calculated and normalized in FPKM as described above from the raw RNAseq data and used for Gene Set Enrichment Analysis (GSEA, Broad Institute).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. All studies must disclose on these points even when the disclosure is negative.
Sample size
For each individual experiments, the sample size was not predetermined before initial experiment. Normally 3 or up to 6 biological repeats were included based on experience or the sample availability. After the initial experiment, power analyses were performed to decide the final sample size.
Data exclusions No data exclusions were taken for this manuscript.
Replication
Each experiment was repeated at least 2-3 times as described in Figure legends . Experimental findings were reliably reproduced between these experiments.
Randomization Mice used in this experiment were randomly assigned to different groups. Patients were randomly selected according to the blood test results.
Blinding N/A Blood was taken from randomly selected patients based on availability and acceptance of consent. Grouping of patients was based on the routine clinical blood test and well accepted standard of anemia. The results of routine blood test, flow cytometry and EBV detection are all detected and reported by machine. No treatment had been given to the cancer patients prior to sample collection. There do not have any subjective bias and personal preference.
Behavioural & social sciences study design All studies must disclose on these points even when the disclosure is negative. 
Study description
Data exclusions
If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Mycoplasma contamination
Cell lines were routinely validated and they are free of mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Palaeontology Specimen provenance
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).
Specimen deposition
Indicate where the specimens have been deposited to permit free access by other researchers. Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.
Dating methods
Recruitment
According to our experiments and with the patient's consent, we divided inpatients (clearly diagnosed stage III-IV cancer patients) of Oncology Department of xinqiao hospital into different groups according to the blood test results. Patients in different groups are randomly selected into our experiments. At the same time, the healthy volunteers were randomly selected from Medical examination center. We do not have any potential self-delection bias or other biases.
ChIP-seq Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links
May remain private before publication. 
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Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
